Goldberg Harley, Firtch William, Tyburski Mark, Pressman Alice, Ackerson Lynn, Hamilton Luisa, Smith Wayne, Carver Ryan, Maratukulam Annu, Won Lawrence A, Carragee Eugene, Avins Andrew L
Kaiser Permanente Northern California Spine Care Program, San Jose2Division of Research, Kaiser Permanente Northern California, Oakland.
Kaiser Permanente Northern California Spine Care Program, Redwood City.
JAMA. 2015 May 19;313(19):1915-23. doi: 10.1001/jama.2015.4468.
Oral steroids are commonly used to treat acute sciatica due to a herniated disk but have not been evaluated in an appropriately powered clinical trial.
To determine if oral prednisone is more effective than placebo in improving function and pain among patients with acute sciatica.
DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled clinical trial conducted from 2008 to 2013 in a large integrated health care delivery system in Northern California. Adults (n=269) with radicular pain for 3 months or less, an Oswestry Disability Index (ODI) score of 30 or higher (range, 0-100; higher scores indicate greater dysfunction), and a herniated disk confirmed by magnetic resonance imaging were eligible.
Participants were randomly assigned in a 2:1 ratio to receive a tapering 15-day course of oral prednisone (5 days each of 60 mg, 40 mg, and 20 mg; total cumulative dose = 600 mg; n = 181) or matching placebo (n = 88).
The primary outcome was ODI change at 3 weeks; secondary outcomes were ODI change at 1 year, change in lower extremity pain (measured on a 0-10 scale; higher scores indicate more pain), spine surgery, and Short Form 36 Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) scores (0-100 scale; higher scores better).
Observed baseline and 3-week mean ODI scores were 51.2 and 32.2 for the prednisone group and 51.1 and 37.5 for the placebo group, respectively. The prednisone-treated group showed an adjusted mean 6.4-point (95% CI, 1.9-10.9; P = .006) greater improvement in ODI scores at 3 weeks than the placebo group and a mean 7.4-point (95% CI, 2.2-12.5; P = .005) greater improvement at 52 weeks. Compared with the placebo group, the prednisone group showed an adjusted mean 0.3-point (95% CI, -0.4 to 1.0; P = .34) greater reduction in pain at 3 weeks and a mean 0.6-point (95% CI, -0.2 to 1.3; P = .15) greater reduction at 52 weeks. The prednisone group showed an adjusted mean 3.3-point (95% CI, 1.3-5.2; P = .001) greater improvement in the SF-36 PCS score at 3 weeks, no difference in the SF-36 PCS score at 52 weeks (mean, 2.5; 95% CI, -0.3 to 5.4; P = .08), no change in the SF-36 MCS score at 3 weeks (mean, 2.2; 95% CI, -0.4 to 4.8; P = .10), and an adjusted 3.6-point (95% CI, 0.6-6.7; P = .02) greater improvement in the SF-36 MCS score at 52 weeks. There were no differences in surgery rates at 52-week follow-up. Having 1 or more adverse events at 3-week follow-up was more common in the prednisone group than in the placebo group (49.2% vs 23.9%; P < .001).
Among patients with acute radiculopathy due to a herniated lumbar disk, a short course of oral steroids, compared with placebo, resulted in modestly improved function and no improvement in pain.
clinicaltrials.gov Identifier: NCT00668434.
口服类固醇常用于治疗因椎间盘突出导致的急性坐骨神经痛,但尚未在具有足够样本量的临床试验中进行评估。
确定口服泼尼松在改善急性坐骨神经痛患者的功能和疼痛方面是否比安慰剂更有效。
设计、地点和参与者:2008年至2013年在北加利福尼亚州一个大型综合医疗保健系统中进行的随机、双盲、安慰剂对照临床试验。患有神经根性疼痛3个月或更短时间、奥斯威斯利功能障碍指数(ODI)评分30或更高(范围为0 - 100;分数越高表明功能障碍越严重)且经磁共振成像证实有椎间盘突出的成年人(n = 269)符合条件。
参与者以2:1的比例随机分配,接受为期15天逐渐减量的口服泼尼松疗程(60毫克、40毫克和20毫克各服用5天;总累积剂量 = 600毫克;n = 181)或匹配的安慰剂(n = 88)。
主要结局是3周时ODI的变化;次要结局是1年时ODI的变化、下肢疼痛的变化(采用0 - 10分制测量;分数越高表明疼痛越严重)、脊柱手术以及简短健康调查问卷(SF - 36)身体成分总结(PCS)和精神成分总结(MCS)评分(0 - 100分制;分数越高越好)。
泼尼松组观察到的基线和3周时的平均ODI评分分别为51.2和32.2,安慰剂组分别为51.1和37.5。泼尼松治疗组在3周时ODI评分的调整后平均改善比安慰剂组高6.4分(95%置信区间,1.9 - 10.9;P = 0.006),在52周时平均高7.4分(95%置信区间,2.2 - 12.5;P = 0.005)。与安慰剂组相比,泼尼松组在3周时疼痛的调整后平均减轻幅度高0.3分(95%置信区间, - 0.4至1.0;P = 0.34),在52周时平均高0.6分(95%置信区间, - 0.2至1.3;P = 0.15)。泼尼松组在3周时SF - 36 PCS评分的调整后平均改善高3.3分(95%置信区间,1.3 - 5.2;P = 0.001),52周时SF - 36 PCS评分无差异(平均值为2.5;95%置信区间, - 0.3至5.4;P = 0.08),3周时SF - 36 MCS评分无变化(平均值为2.2;95%置信区间, - 0.4至4.8;P = 0.10),52周时SF - 36 MCS评分的调整后改善高3.6分(95%置信区间,0.6 - 6.7;P = 0.02)。52周随访时手术率无差异。在3周随访时有1种或更多不良事件在泼尼松组比安慰剂组更常见(49.2%对23.9%;P < 0.001)。
在因腰椎间盘突出导致急性神经根病的患者中,与安慰剂相比,短期口服类固醇导致功能适度改善,但疼痛无改善。
clinicaltrials.gov标识符:NCT00668434。